Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NewLink Genetics NLNK

Healthcare Biotechnology
Lumos Pharma Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare and neglected diseases. The company's therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, is in late-stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD).


NDAQ:NLNK - Post by User

NewLink Genetics > WHO will test Newlink
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by jawcrusheron Oct 17, 2014 5:40pm
409 Views
Post# 23039399

WHO will test Newlink

WHO will test Newlinkhttps://www.who.int/immunization/diseases/ebola/WHO_consultation_ebola_sep2014/en/index1.html


From website go to this pdf to see trial program.

Overview of vaccine development pathway
pdf, 953kb
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities